End Of Phase II Meetings Used By Less Than Half The Firms In PwC Survey
Fewer than half of drug companies participating in a PricewaterhouseCoopers survey participated in a meeting with FDA at the conclusion of Phase II studies
You may also be interested in...
Problems in clinical trial design for IDM Pharma's osteosarcoma drug Junovan (mifamurtide) could have been rectified if the sponsor had held an end-of-Phase II meeting with FDA prior to study initiation, the agency said in briefing documents for a May 9 meeting of the Oncologic Drugs Advisory Committee
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals